Comera Life Sciences Holdings, Inc. CMRA
Set alert
0.00 USD 0.00 0.00%
At close · Oct 29
0.0001 Day range 0.0001
0.0001 52-week range 0.0001
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 3.07K
- Vol
- 730
- Avg vol
- 501
- EPS
- -0.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- 0.00
- Beta
- 0.45
- Short ratio
- 0.84
- Inst. own
- 13.56%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.21206
- 200-d avg
- 0.542355
- 1y target
- 0.00
2Y chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| RSI: Oversold | Sep 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| SMA: Bullish | May 27, 2025 | 1 year ago |
| RSI: Overbought | May 27, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| RSI: Oversold | Apr 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 15, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
Key statistics
- Market cap
- 2.57M
- Enterprise value
- 5.97M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 2.57
- Price / book
- 0.00
- EPS (TTM)
- -0.22
- Beta
- 0.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.00M
- Revenue growth
- -42.00%
- Free cash flow
- -2.99M
- Total cash
- 1.77M
- Total debt
- 561.47K
- Return on equity
- -1629.02%
- Shares outstanding
- 30.74M
- Short % of float
- 1.36%
- 50-day average
- 0.21206
- 200-day average
- 0.542355
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CMRA Revenue — quarterly 136.31K
CMRA Net income — quarterly -2.15M
CMRA EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.10 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.08 | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | -0.13 | — | — |
| Mar 16, 2023 | Dec 1, 2022 | 0.00 | -0.18 | — | — |
| Nov 10, 2022 | Sep 1, 2022 | 0.00 | -0.20 | — | — |
About Comera Life Sciences Holdings, Inc.
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- comeralifesciences.com
News
- Actinium Pharmaceuticals (NYSE:ATNM) vs. Comera Life Sciences (NASDAQ:CMRA) Critical Comparison
- Critical Contrast: Palatin Technologies (PINK:PTNT) vs. Comera Life Sciences (NASDAQ:CMRA)
- Reviewing Comera Life Sciences (NASDAQ:CMRA) & Zymeworks (NYSE:ZYME)
- Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option
- Comera Life Sciences Announces Process Exploring Strategic Alternatives
- Comera Life Sciences Appoints Dorothy Clarke to Board of Directors
- Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights
- Comera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery Conference
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on CMRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BANERJEE SIRSHENDU ROOPOM | Director | Stock Award(Grant) | Jan 3, 2023 | 28,956 |
| CAMPBELL MICHAEL GERARD | Chief Financial Officer | Purchase | Nov 26, 2023 | 35,000 |
| CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 10, 2023 | 7,368,390 |
| FINCK BARBARA K | Director | Stock Award(Grant) | Jan 3, 2023 | 23,033 |
| FLOWERS KIRSTEN | Director | Stock Award(Grant) | Jan 3, 2023 | 22,199 |
| MAHONEY ROBERT PATRICK | Officer | Purchase | Aug 13, 2023 | 124,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lake Street Advisors Group, LLC | 1.16% | 316,469 | 154.25K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.22% | 60,008 | 29.25K | Jun 29, 2023 |
| HighTower Advisors, LLC | 0.18% | 47,600 | 23.20K | Jun 29, 2023 |
| Vanguard Group Inc | 0.16% | 44,098 | 21.49K | Jun 29, 2023 |
| State Street Corporation | 0.11% | 29,600 | 14.43K | Jun 29, 2023 |
| Osaic Holdings Inc | 0.07% | 18,750 | 9.14K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.16% | 42,717 | 21.79K | May 30, 2023 |
| Vanguard Extended Market Index Fund | 0.16% | 44,098 | 21.49K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.04% | 10,925 | 5.57K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 4,547 | 2.32K | May 30, 2023 |